

CNMV
Markets Directorate General
C/ Edison 4
28006 Madrid

Colmenar Viejo (Madrid), July 21, 2026

In accordance with article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

With regard to the “Other Relevant Information” announcement published on June 30, 2026 (registration number 41635) concerning the composition of the Board of Directors and its Committees, the Company reported that Ms. María Victoria Mateos Manteca, appointed as an independent director by the General Shareholders’ Meeting held on that date, had been unable to accept the position because, as of that time, she had not obtained the required authorization of compatibility from the competent authorities and entities.

The effectiveness of said appointment had been made conditional, in accordance with the corresponding resolution of the General Shareholders’ Meeting, upon the valid acceptance of the position by the appointee within a period of twenty (20) days from the date of the General Shareholders’ Meeting.

The Company reports that, as this period has elapsed, Ms. María Victoria Mateos Manteca has not obtained the necessary authorization to accept the position; therefore, the appointment has not been accepted under the terms set forth in the resolution of the General Shareholders’ Meeting.

Consequently, the aforementioned appointment has not taken effect, and the composition of the Board of Directors of Pharma Mar, S.A. remains at eleven (11) members, as previously communicated in the aforementioned Other Relevant Information dated June 30, 2026.